Clinical Trials

35 enrolled

Pancreatic Neoplasms

NCT06869213 2025-10-02

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

30 enrolled

Esophageal Neoplasms

NCT06869226 2025-10-02

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

283 enrolled

Esophageal Neoplasms

NCT06463665 2025-09-26

VIRO-25

142 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT06770452 2025-09-23

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

32 enrolled

Pancreatic Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

520 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04159142 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

414 enrolled

Triple Negative Breast Neoplasms

NCT06313970 2025-09-03

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

58 enrolled

Pancreatic Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

37 enrolled

Triple Negative Breast Neoplasms

NCT07125547 2025-08-15

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

35 enrolled

Ureteral Neoplasms

NCT06423326 2025-07-30

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT06441890 2025-07-14

BRE-10

28 enrolled

Breast Neoplasms

NCT05272696 2025-07-01

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

86 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT03645928 2025-06-19

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

DermatologicHead & NeckThoracic

245 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06446726 2025-06-06

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT05241249 2025-06-05

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

37 enrolled

Adenocarcinoma, Pancreatic Neoplasms

NCT06964906 2025-05-11

NeoHunter

140 enrolled

Breast Neoplasms

NCT05859750 2024-12-16

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

78 enrolled

Pancreatic Neoplasms

NCT06538896 2024-11-26

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

20 enrolled

Triple Negative Breast Neoplasms

NCT06705127 2024-11-26

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.

30 enrolled

HR-positive,HER2-negative Breast Cancer

NCT05766800 2024-09-19

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06359275 2024-06-25

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

81 enrolled

Pancreatic Neoplasms

NCT04865250 2024-05-16

iReP

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05098119 2024-03-26

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

43 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06165900 2024-01-03

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

136 enrolled

Breast Neoplasms

NCT03964753 2023-10-10

NTNC

202 enrolled

Esophageal Squamous Cell Carcinoma

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

35 enrolled

Triple Negative Breast Neoplasms

NCT04807140 2023-04-14

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

57 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT05761470 2023-03-09

IMPARP

66 enrolled

Her-2 Negative Breast Cancer

NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

50 enrolled

Gallbladder Neoplasms

NCT05000892 2022-12-02

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Head & NeckOther neoplasm

15 enrolled

Salivary Gland Malignant Neoplasms

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

53 enrolled